Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Transl Med ; 2(37): 37ra44, 2010 Jun 23.
Article in English | MEDLINE | ID: mdl-20574068

ABSTRACT

The clinical symptomatology in the X-linked Wiskott-Aldrich syndrome (WAS), a combined immunodeficiency and autoimmune disease resulting from WAS protein (WASp) deficiency, reflects the underlying coexistence of an impaired T helper 1 (TH1) immunity alongside intact TH2 immunity. This suggests a role for WASp in patterning T(H) subtype immunity, yet the molecular basis for the TH1-TH2 imbalance in human WAS is unknown. We have discovered a nuclear role for WASp in the transcriptional regulation of the TH1 regulator gene TBX21 at the chromatin level. In primary TH1-differentiating cells, a fraction of WASp is found in the nucleus, where it is recruited to the proximal promoter locus of the TBX21 gene, but not to the core promoter of GATA3 (a TH2 regulator gene) or RORc (a TH17 regulator gene). Genome-wide mapping demonstrates association of WASp in vivo with the gene-regulatory network that orchestrates TH1 cell fate choice in the human TH cell genome. Functionally, nuclear WASp associates with H3K4 trimethyltransferase [RBBP5 (retinoblastoma-binding protein 5)] and H3K9/H3K36 tridemethylase [JMJD2A (Jumonji domain-containing protein 2A)] proteins, and their enzymatic activity in vitro and in vivo is required for achieving transcription-permissive chromatin dynamics at the TBX21 proximal promoter in primary differentiating TH1 cells. During TH1 differentiation, the loss of WASp accompanies decreased enrichment of RBBP5 and, in a subset of WAS patients, also of filamentous actin at the TBX21 proximal promoter locus. Accordingly, human WASp-deficient TH cells, from natural mutation or RNA interference-mediated depletion, demonstrate repressed TBX21 promoter dynamics when driven under TH1-differentiating conditions. These chromatin derangements accompany deficient T-BET messenger RNA and protein expression and impaired TH1 function, defects that are ameliorated by reintroducing WASp. Our findings reveal a previously unappreciated role of WASp in the epigenetic control of T-BET transcription and provide a new mechanism for the pathogenesis of WAS by linking aberrant histone methylation at the TBX21 promoter to dysregulated adaptive immunity.


Subject(s)
Cell Nucleus/metabolism , Immunity/immunology , Th1 Cells/immunology , Wiskott-Aldrich Syndrome Protein/metabolism , Wiskott-Aldrich Syndrome/immunology , Wiskott-Aldrich Syndrome/physiopathology , Actins/metabolism , Cell Differentiation , Cells, Cultured , Cellular Reprogramming/genetics , Chromatin/metabolism , DNA/metabolism , Epigenesis, Genetic , Genetic Loci/genetics , Genome, Human/genetics , Histones/metabolism , Humans , Methylation , Mutant Proteins/metabolism , Promoter Regions, Genetic/genetics , Protein Binding , Protein Transport , T-Box Domain Proteins/genetics , T-Box Domain Proteins/metabolism , Th1 Cells/cytology , Transcription, Genetic , Wiskott-Aldrich Syndrome/metabolism , Wiskott-Aldrich Syndrome/pathology , Wiskott-Aldrich Syndrome Protein/deficiency
2.
J Immunol ; 180(12): 8361-8, 2008 Jun 15.
Article in English | MEDLINE | ID: mdl-18523303

ABSTRACT

Microsomal PGE synthase-1 (mPGES-1) is an inducible enzyme that acts downstream of cyclooxygenase and specifically catalyzes the conversion of PGH(2) to PGE(2). The present study demonstrates the effect of genetic deletion of mPGES-1 on the developing immunologic responses and its impact on the clinical model of bovine collagen-induced arthritis. mPGES-1 null and heterozygous mice exhibited decreased incidence and severity of arthritis compared with wild-type mice in a gene dose-dependent manner. Histopathological examination revealed significant reduction in lining hyperplasia and tissue destruction in mPGES-1 null mice compared with their wild-type littermates. mPGES-1 deficient mice also exhibited attenuation of mechanical nociception in a gene dose-dependent manner. In addition, mPGES-1 null and heterozygous mice showed a marked reduction of serum IgG against type II collagen, including subclasses IgG1, IgG2a, IgG2b, IgG2c, and IgG3, compared with wild-type mice, which correlated with the reduction in observed inflammatory features. These results demonstrate for the first time that deficiency of mPGES-1 inhibits the development of collagen-induced arthritis, at least in part, by blocking the development of a humoral immune response against type II collagen. Pharmacologic inhibition of mPGES-1 may therefore impact both the inflammation and the autoimmunity associated with human diseases such as rheumatoid arthritis.


Subject(s)
Arthritis, Experimental/enzymology , Arthritis, Experimental/therapy , Collagen Type II/immunology , Cyclooxygenase 1/deficiency , Cyclooxygenase 1/genetics , Immunoglobulin G , Membrane Proteins/deficiency , Membrane Proteins/genetics , Microsomes/enzymology , Severity of Illness Index , Animals , Arthritis, Experimental/genetics , Arthritis, Experimental/immunology , Cattle , Collagen Type II/administration & dosage , Cyclooxygenase 1/physiology , Cyclooxygenase 2/biosynthesis , Cyclooxygenase 2/genetics , Cyclooxygenase 2/physiology , Female , Gene Deletion , Genetic Carrier Screening , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Immunoglobulin G/physiology , Immunoglobulin M/biosynthesis , Incidence , Male , Membrane Proteins/physiology , Mice , Mice, Inbred DBA , Mice, Knockout , RNA, Messenger/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...